chr19-10987904-C-G

Variant summary

Our verdict is Likely benign. The variant received -3 ACMG points: 0P and 3B. BP4_ModerateBS1_Supporting

The NM_001387283.1(SMARCA4):​c.1098C>G​(p.Ile366Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,612,886 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I366F) has been classified as Uncertain significance.

Frequency

Genomes: š‘“ 0.000013 ( 0 hom., cov: 32)
Exomes š‘“: 0.000016 ( 0 hom. )

Consequence

SMARCA4
NM_001387283.1 missense

Scores

3
4
12

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:1

Conservation

PhyloP100: -0.0520

Publications

1 publications found
Variant links:
Genes affected
SMARCA4 (HGNC:11100): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
SMARCA4 Gene-Disease associations (from GenCC):
  • Coffin-Siris syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
  • intellectual disability, autosomal dominant 16
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • rhabdoid tumor predisposition syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • uterine corpus sarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • familial rhabdoid tumor
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary nonpolyposis colon cancer
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -3 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.18166867).
BS1
Variant frequency is greater than expected in population amr. GnomAdExome4 allele frequency = 0.0000164 (24/1460666) while in subpopulation AMR AF = 0.000246 (11/44700). AF 95% confidence interval is 0.000137. There are 0 homozygotes in GnomAdExome4. There are 14 alleles in the male GnomAdExome4 subpopulation. Median coverage is 34. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SMARCA4NM_001387283.1 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 36 ENST00000646693.2 NP_001374212.1
SMARCA4NM_003072.5 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 35 ENST00000344626.10 NP_003063.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SMARCA4ENST00000646693.2 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 36 NM_001387283.1 ENSP00000495368.1
SMARCA4ENST00000344626.10 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 35 1 NM_003072.5 ENSP00000343896.4
SMARCA4ENST00000643549.1 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 35 ENSP00000493975.1
SMARCA4ENST00000541122.6 linkc.1098C>G p.Ile366Met missense_variant Exon 7 of 35 5 ENSP00000445036.2
SMARCA4ENST00000643296.1 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 34 ENSP00000496635.1
SMARCA4ENST00000644737.1 linkc.1098C>G p.Ile366Met missense_variant Exon 6 of 34 ENSP00000495548.1
SMARCA4ENST00000589677.5 linkc.1098C>G p.Ile366Met missense_variant Exon 7 of 35 5 ENSP00000464778.1
SMARCA4ENST00000643995.1 linkc.510C>G p.Ile170Met missense_variant Exon 3 of 32 ENSP00000496004.1

Frequencies

GnomAD3 genomes
AF:
0.0000131
AC:
2
AN:
152220
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.0000373
AC:
9
AN:
241244
AF XY:
0.0000532
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000204
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000189
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000164
AC:
24
AN:
1460666
Hom.:
0
Cov.:
34
AF XY:
0.0000193
AC XY:
14
AN XY:
726608
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33458
American (AMR)
AF:
0.000246
AC:
11
AN:
44700
Ashkenazi Jewish (ASJ)
AF:
0.0000383
AC:
1
AN:
26124
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39688
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86180
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52906
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5344
European-Non Finnish (NFE)
AF:
0.00000989
AC:
11
AN:
1111940
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60326
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
1
3
4
6
7
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152220
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74372
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41454
American (AMR)
AF:
0.00
AC:
0
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5196
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4838
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68038
Other (OTH)
AF:
0.000478
AC:
1
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000151
ExAC
AF:
0.0000248
AC:
3

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Rhabdoid tumor predisposition syndrome 2 Uncertain:2
Dec 29, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 366 of the SMARCA4 protein (p.Ile366Met). This variant is present in population databases (rs532242119, gnomAD 0.02%). This missense change has been observed in individual(s) with breast cancer, SMARCA4-related conditions (PMID: 28202063, 37500730). ClinVar contains an entry for this variant (Variation ID: 484848). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SMARCA4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Jan 09, 2024
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Jun 16, 2022
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Dec 22, 2021
Sema4, Sema4
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Intellectual disability, autosomal dominant 16 Uncertain:1
Jul 15, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Rhabdoid tumor predisposition syndrome 2;C3553249:Intellectual disability, autosomal dominant 16 Uncertain:1
Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.31
BayesDel_addAF
Benign
-0.15
T
BayesDel_noAF
Benign
-0.18
CADD
Benign
20
DANN
Benign
0.93
DEOGEN2
Uncertain
0.43
T;.;T;.;.;.;.;.;.;.;T;.;.;.;.;.;T;T
Eigen
Benign
-0.57
Eigen_PC
Benign
-0.50
FATHMM_MKL
Uncertain
0.82
D
LIST_S2
Pathogenic
0.97
.;D;.;.;.;.;D;.;.;.;D;.;D;D;D;D;D;D
M_CAP
Pathogenic
0.33
D
MetaRNN
Benign
0.18
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
-0.28
T
MutationAssessor
Benign
1.9
L;.;.;.;L;L;.;L;L;L;L;L;L;L;L;L;.;.
PhyloP100
-0.052
PrimateAI
Pathogenic
0.90
D
PROVEAN
Benign
-2.0
N;.;.;.;.;.;.;.;.;.;N;.;N;.;N;.;N;N
REVEL
Uncertain
0.42
Sift
Benign
0.21
T;.;.;.;.;.;.;.;.;.;T;.;T;.;T;.;T;T
Sift4G
Benign
0.40
T;.;.;.;.;.;.;.;.;.;T;.;T;T;T;T;T;T
Polyphen
0.21
B;.;B;.;.;.;.;.;.;.;B;.;.;.;.;.;.;B
Vest4
0.74
MutPred
0.40
Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);Gain of MoRF binding (P = 0.0815);
MVP
0.73
MPC
2.2
ClinPred
0.10
T
GERP RS
-0.48
RBP_binding_hub_radar
0.92
RBP_regulation_power_radar
2.7
Varity_R
0.39
gMVP
0.80
Mutation Taster
=74/26
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs532242119; hg19: chr19-11098580; API